Animal studies and additional testing of SB623 for other diseases
First written in FY2017. 3 of 4 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「Animal studies have produced favorable results for Parkinson's disease and spinal cord injury, and the company will conduct the additional studies required to obtain approval to conduct clinical trials. For Alzheimer's disease and other conditions, the company will investigate the potential indications in nonclinical studies (in vivo studies).」
The policy of proceeding with additional studies of SB623 for Parkinson's disease and spinal cord injury, and investigating potential indications through nonclinical studies for Alzheimer's disease and other conditions, has been reaffirmed. - FY2020RestatedAnnual report
「Animal studies have produced favorable results for Parkinson's disease and spinal cord injury, and the company will conduct the additional studies required to obtain approval to conduct clinical trials. For Alzheimer's disease and other conditions, the company will investigate the potential indications in animal studies.」
The policy of proceeding with additional studies for Parkinson's disease and spinal cord injury, and investigating potential indications in animal studies for Alzheimer's disease and other conditions, has been reaffirmed. - FY2019RestatedAnnual report
「Animal studies have produced favorable results for Parkinson's disease and spinal cord injury, and the company will conduct the additional studies required to obtain approval to conduct clinical trials. For Alzheimer's disease and other conditions, the company will investigate the potential indications in animal studies.」
The policy of proceeding with additional studies for Parkinson's disease and spinal cord injury, and investigating potential indications through animal studies for Alzheimer's disease and other conditions, has been reaffirmed. - FY2017First statedAnnual report
「Animal studies have produced favorable results for Parkinson's disease and spinal cord injury, and the company will conduct the additional studies required to obtain approval to conduct clinical trials. For Alzheimer's disease and other conditions, the company will investigate the potential indications in animal studies.」
The policy is to proceed with additional studies for Parkinson's disease and spinal cord injury, and to investigate potential indications in animal studies for Alzheimer's disease and other conditions.